Protocol No.: XPORT-MF-034

A Phase 1 / Phase 3 Study to Evaluate the Efficacy and Safety of Selinexor, A Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib in Treatment-Naïve Patients with Myelofibrosis
Principal Investigator
Bhatnagar, Bhavana
Phase
III
Age Group
Adult
Applicable Disease Site
Other Cancers
Participating Institution
Wheeling Hospital
Contact
Maher Kali, MD
Clinical Research Specialist-WVUCI
Phone: +1 304-243-7045

View on ClinicalTrials.gov